Tatsuya Kobayashi, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Astrocytoma | 4 | 2020 | 778 | 0.780 |
Why?
|
Limb Deformities, Congenital | 1 | 2018 | 136 | 0.570 |
Why?
|
Tracheoesophageal Fistula | 1 | 2018 | 130 | 0.550 |
Why?
|
Brain Neoplasms | 11 | 2021 | 8892 | 0.530 |
Why?
|
Gliosarcoma | 2 | 2017 | 113 | 0.520 |
Why?
|
Eyelids | 1 | 2018 | 280 | 0.520 |
Why?
|
Gene Expression Regulation, Enzymologic | 2 | 2013 | 1172 | 0.510 |
Why?
|
Microcephaly | 1 | 2018 | 429 | 0.460 |
Why?
|
Sulfotransferases | 1 | 2013 | 149 | 0.410 |
Why?
|
Gene Expression Regulation, Neoplastic | 5 | 2021 | 8422 | 0.290 |
Why?
|
STAT3 Transcription Factor | 2 | 2021 | 870 | 0.250 |
Why?
|
Caspase 3 | 1 | 2007 | 729 | 0.250 |
Why?
|
Glioma | 3 | 2020 | 3395 | 0.220 |
Why?
|
Nimustine | 1 | 2021 | 2 | 0.200 |
Why?
|
MicroRNAs | 1 | 2018 | 3766 | 0.200 |
Why?
|
Lomustine | 1 | 2021 | 60 | 0.200 |
Why?
|
Carbazoles | 1 | 2021 | 220 | 0.170 |
Why?
|
Sulfones | 1 | 2021 | 443 | 0.160 |
Why?
|
Protoporphyrins | 1 | 2016 | 165 | 0.140 |
Why?
|
Glioblastoma | 2 | 2021 | 3471 | 0.130 |
Why?
|
Intraoperative Care | 1 | 2020 | 759 | 0.130 |
Why?
|
Signal Transduction | 2 | 2021 | 23234 | 0.130 |
Why?
|
Aminolevulinic Acid | 1 | 2016 | 141 | 0.130 |
Why?
|
Oligodendroglioma | 1 | 2017 | 283 | 0.130 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2018 | 916 | 0.120 |
Why?
|
Transforming Growth Factor beta1 | 1 | 2018 | 607 | 0.120 |
Why?
|
Somatomedins | 1 | 2014 | 176 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2018 | 606 | 0.110 |
Why?
|
Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2013 | 18 | 0.110 |
Why?
|
Hypoxia-Inducible Factor 1 | 1 | 2014 | 193 | 0.110 |
Why?
|
Chondroitin Sulfates | 1 | 2013 | 175 | 0.100 |
Why?
|
Piperidines | 1 | 2021 | 1645 | 0.100 |
Why?
|
Photosensitizing Agents | 1 | 2016 | 608 | 0.100 |
Why?
|
RANK Ligand | 1 | 2014 | 316 | 0.100 |
Why?
|
PTEN Phosphohydrolase | 1 | 2018 | 1114 | 0.100 |
Why?
|
Glucans | 1 | 2011 | 67 | 0.100 |
Why?
|
Heterozygote | 1 | 2018 | 2785 | 0.090 |
Why?
|
Vimentin | 1 | 2011 | 256 | 0.090 |
Why?
|
Bone Resorption | 1 | 2014 | 717 | 0.090 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2021 | 5164 | 0.090 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2011 | 546 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2017 | 1051 | 0.080 |
Why?
|
Mice, Nude | 4 | 2021 | 3582 | 0.080 |
Why?
|
Flow Cytometry | 1 | 2020 | 5838 | 0.080 |
Why?
|
Loss of Heterozygosity | 1 | 2011 | 659 | 0.080 |
Why?
|
Transplantation, Heterologous | 2 | 2014 | 2368 | 0.080 |
Why?
|
In Situ Hybridization | 1 | 2013 | 1896 | 0.080 |
Why?
|
Pyrimidines | 1 | 2021 | 2979 | 0.080 |
Why?
|
Leiomyoma | 1 | 2014 | 663 | 0.080 |
Why?
|
Osteosarcoma | 1 | 2014 | 888 | 0.080 |
Why?
|
Drug Therapy | 1 | 2011 | 499 | 0.080 |
Why?
|
Cell Line, Tumor | 5 | 2021 | 16737 | 0.080 |
Why?
|
Disease Models, Animal | 2 | 2018 | 17958 | 0.070 |
Why?
|
Chromosomes, Human, Pair 19 | 2 | 2018 | 349 | 0.070 |
Why?
|
Neoplasm Recurrence, Local | 3 | 2021 | 9207 | 0.070 |
Why?
|
Chromosomes, Human, Pair 1 | 2 | 2018 | 639 | 0.060 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 4571 | 0.060 |
Why?
|
Uterine Neoplasms | 1 | 2014 | 1444 | 0.060 |
Why?
|
Mice, Inbred BALB C | 3 | 2021 | 6112 | 0.060 |
Why?
|
Antigens, Neoplasm | 1 | 2011 | 1989 | 0.050 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2021 | 3554 | 0.050 |
Why?
|
Radiosurgery | 1 | 2012 | 1335 | 0.050 |
Why?
|
Mice, Knockout | 1 | 2018 | 14297 | 0.050 |
Why?
|
Prognosis | 3 | 2018 | 29337 | 0.050 |
Why?
|
Mice | 6 | 2021 | 80550 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2511 | 0.050 |
Why?
|
Injections, Intraperitoneal | 1 | 2021 | 407 | 0.050 |
Why?
|
DNA Modification Methylases | 1 | 2021 | 205 | 0.050 |
Why?
|
Survival Analysis | 1 | 2013 | 10172 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2018 | 11884 | 0.040 |
Why?
|
DNA Repair Enzymes | 1 | 2021 | 344 | 0.040 |
Why?
|
Carrier Proteins | 1 | 2013 | 4931 | 0.040 |
Why?
|
Multivariate Analysis | 1 | 2013 | 12138 | 0.040 |
Why?
|
Cell Movement | 1 | 2011 | 5172 | 0.040 |
Why?
|
Neoplasm Transplantation | 2 | 2014 | 2012 | 0.040 |
Why?
|
Methylation | 1 | 2021 | 1075 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13550 | 0.040 |
Why?
|
Male | 9 | 2020 | 354908 | 0.040 |
Why?
|
Cell Survival | 2 | 2021 | 5771 | 0.040 |
Why?
|
Cytokines | 1 | 2013 | 7235 | 0.040 |
Why?
|
Female | 8 | 2021 | 386085 | 0.040 |
Why?
|
Child, Preschool | 2 | 2013 | 41660 | 0.040 |
Why?
|
Humans | 14 | 2021 | 752411 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2018 | 515 | 0.040 |
Why?
|
Animals | 6 | 2021 | 166811 | 0.040 |
Why?
|
Enzyme Activation | 2 | 2014 | 3597 | 0.030 |
Why?
|
Disease Progression | 1 | 2013 | 13405 | 0.030 |
Why?
|
Spheroids, Cellular | 1 | 2016 | 329 | 0.030 |
Why?
|
Neoplasm, Residual | 1 | 2020 | 994 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1265 | 0.030 |
Why?
|
Adult | 6 | 2020 | 216927 | 0.030 |
Why?
|
Prostatic Neoplasms | 1 | 2016 | 11265 | 0.030 |
Why?
|
Chromosome Deletion | 1 | 2018 | 1387 | 0.030 |
Why?
|
Administration, Oral | 1 | 2021 | 4002 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2021 | 10360 | 0.030 |
Why?
|
Child | 2 | 2013 | 79004 | 0.030 |
Why?
|
Adolescent | 2 | 2013 | 86766 | 0.030 |
Why?
|
Cell Hypoxia | 1 | 2014 | 660 | 0.020 |
Why?
|
Tumor Suppressor Proteins | 1 | 2021 | 2796 | 0.020 |
Why?
|
Aged | 3 | 2013 | 166585 | 0.020 |
Why?
|
Histones | 1 | 2021 | 2567 | 0.020 |
Why?
|
Focal Adhesion Protein-Tyrosine Kinases | 1 | 2011 | 185 | 0.020 |
Why?
|
Photochemotherapy | 1 | 2016 | 808 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 476 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2011 | 480 | 0.020 |
Why?
|
Progesterone | 1 | 2014 | 751 | 0.020 |
Why?
|
Mice, Inbred NOD | 1 | 2014 | 1809 | 0.020 |
Why?
|
Mice, SCID | 1 | 2014 | 2617 | 0.020 |
Why?
|
Middle Aged | 3 | 2013 | 217039 | 0.020 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20351 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 35932 | 0.020 |
Why?
|
Estrogens | 1 | 2014 | 1516 | 0.020 |
Why?
|
Hemoglobins | 1 | 2012 | 1510 | 0.020 |
Why?
|
Bone Marrow Cells | 1 | 2014 | 2416 | 0.020 |
Why?
|
Transforming Growth Factor beta | 1 | 2014 | 1945 | 0.020 |
Why?
|
Infant | 1 | 2007 | 35675 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2021 | 5594 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2014 | 5148 | 0.010 |
Why?
|
Mutation | 2 | 2018 | 29706 | 0.010 |
Why?
|
Antibodies | 1 | 2011 | 2412 | 0.010 |
Why?
|
Regression Analysis | 1 | 2012 | 6358 | 0.010 |
Why?
|
Neoplasm Metastasis | 1 | 2012 | 4862 | 0.010 |
Why?
|
Tumor Microenvironment | 1 | 2014 | 3755 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 2011 | 3599 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2014 | 18915 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2021 | 64250 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2012 | 6792 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2012 | 13167 | 0.000 |
Why?
|
Prospective Studies | 1 | 2012 | 53809 | 0.000 |
Why?
|
Aged, 80 and over | 1 | 2012 | 58299 | 0.000 |
Why?
|
Breast Neoplasms | 1 | 2012 | 20840 | 0.000 |
Why?
|